By InvitationNot Applicable

CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)

United States800 participantsStarted 2021-04-28

Plain-language summary

This is a Prospective, observational research study for patients with NMOSD under the care of a licensed neurologist. Approximately 800 patients and 35 clinical sites in North America will be recruited to participate with no defined upper limit for either target.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Has a diagnosis of NMOSD at the time of enrollment according to the 2015 IPND consensus diagnostic criteria for NMOSD†.
✓. Age 18 years or older at the time of enrollment.
✓. Willing to provide Personal Information.

Exclusion criteria

✕. Has had a clinically confirmed NMOSD neuro-episode within the 12 weeks prior to enrollment.
✕. Is participating or planning to participate in a double-blind randomized trial for an NMOSD drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.

What they're measuring

NMO epidemiology, presentation, natural history, management, and outcomes

Timeframe: A minimum of 10 years from last patient enrolled

Trial details

NCT IDNCT04886492

SponsorCorEvitas

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2099-01

View on ClinicalTrials.gov More Neuromyelitis Optica Spectrum Disorder trials